Characterizing genetic and protein changes in adult AML patients with specific rearrangements
Novel Approaches to Target MECOM/EVI1 in Acute Myeloid Leukemia
NA · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT05839392
This study is trying to learn more about the genetic and protein changes in adults with a specific type of acute myeloid leukemia to improve understanding and treatment options.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 24 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto (other) |
| Locations | 1 site (Piacenza) |
| Trial ID | NCT05839392 on ClinicalTrials.gov |
What this trial studies
This academic, multicenter study focuses on patients with acute myeloid leukemia (AML) who have MECOM or atypical 3q26 rearrangements. It aims to collect and analyze bone marrow samples and biopsies to characterize the genome, transcriptome, and proteome of these patients. The study will gather data before and after treatment, as well as at relapse, to better understand the biological underpinnings of this specific AML subtype.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with AML featuring MECOM or atypical 3q26 rearrangements.
Not a fit: Patients with AML who do not have MECOM or atypical 3q26 rearrangements may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and targeted therapies for AML patients with MECOM or atypical 3q26 rearrangements.
How similar studies have performed: While this approach is focused on a specific genetic alteration in AML, similar studies have shown promise in characterizing other subtypes of leukemia, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * AML with MECOM or atypical 3q26 rearrangements. * Age ≥18. * Signed written informed consent according to ICH/EU/GCP and national local laws. Exclusion Criteria: * None
Where this trial is running
Piacenza
- Ematologia — Piacenza, Italy (RECRUITING)
Study contacts
- Principal investigator: Giovanni Roti — Department of Medicine and Surgery, University of Parma, Parma
- Study coordinator: Paola Fazi
- Email: p.fazi@gimema.it
- Phone: 0670390528
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: AML, Adult